Exact Mass: 449.1562
Exact Mass Matches: 449.1562
Found 500 metabolites which its exact mass value is equals to given mass value 449.1562
,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
Glisoxepide
Glisoxepide is one of the sulphonamide-derived oral antidiabetic drugs. It inhibits the uptake of bile acids into isolated rat hepatocytes. However it inhibits taurocholate uptake only in the absence of sodium ions. Glisoxepide uptake could be further inhibited by blockers of the hepatocellular monocarboxylate transporter, by the loop diuretic bumetanide, by 4,4-diisothiocyano-2,2-stilbenedisulfonate (DIDS) and by sulphate. These results are consistent with the transport of glisoxepide via the transport system for the unconjugated bile acid cholate. (PMID:1618280, 9017793). A - Alimentary tract and metabolism > A10 - Drugs used in diabetes > A10B - Blood glucose lowering drugs, excl. insulins > A10BB - Sulfonylureas C78276 - Agent Affecting Digestive System or Metabolism > C29711 - Anti-diabetic Agent > C97936 - Sulfonylurea Antidiabetic Agent
Bictegravir
Crizotinib
N-[(5-{2-[(6R)-2-Amino-4-oxo-3,4,5,6,7,8-hexahydropyrido[2,3-D]pyrimidin-6-YL]ethyl}-2-thienyl)carbonyl]-L-glutamic acid
N-Ethyl-N-(6,6-dimethyl-2-hepten-4-ynyl)-3-((3,3'-bithiophen-5-yl)methoxy)benzenemethanamine
N-[2,6-Bis(1-methylethyl)phenyl]-N'-[4-[(4-nitrophenyl)thio]phenyl]urea
dihydrogeranylgeranyl-PP
Dihydrogeranylgeranyl-pp is practically insoluble (in water) and a moderately acidic compound (based on its pKa). Dihydrogeranylgeranyl-pp can be found in a number of food items such as chives, nanking cherry, muscadine grape, and towel gourd, which makes dihydrogeranylgeranyl-pp a potential biomarker for the consumption of these food products.
4-(tert-Butyl)-N-({[2-methyl-5-(morpholinosulfonyl)-3-furyl]carbonyl}oxy)benzenecarboximidamide
4-[[4-[Hydroxy(4-methoxyphenyl)methyl]-5-[(4-hydroxyphenyl)methyl]-1-methyl-1H-imidazol-2-yl]amino]-1-methyl-1H-imidazole-2,5-dione
6-(o-hydroxybenzylamino)-2-methylthio-9-beta-glucofuranosilpurine
Ser Thr Asn Glu
3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine
Ala Ala Cys Trp
Ala Ala Trp Cys
Ala Cys Ala Trp
Ala Cys Glu Lys
Ala Cys Glu Gln
Ala Cys Lys Glu
Ala Cys Gln Glu
Ala Cys Trp Ala
Ala Asp Met Asn
Ala Asp Asn Met
Ala Glu Cys Lys
Ala Glu Cys Gln
Ala Glu Lys Cys
Ala Glu Gln Cys
Ala Lys Cys Glu
Ala Lys Glu Cys
Ala Met Asp Asn
Ala Met Asn Asp
Ala Met Gln Thr
Ala Met Thr Gln
Ala Asn Asp Met
Ala Asn Met Asp
Ala Gln Cys Glu
Ala Gln Glu Cys
Ala Gln Met Thr
Ala Gln Thr Met
Ala Ser Ser Trp
Ala Ser Trp Ser
Ala Trp Ala Cys
Ala Trp Cys Ala
Ala Trp Ser Ser
Cys Ala Ala Trp
Cys Ala Glu Gln
Cys Ala Gln Glu
Cys Ala Trp Ala
Cys Cys Lys Pro
Cys Cys Pro Lys
Cys Cys Pro Gln
Cys Cys Gln Pro
Cys Asp Gly Arg
Cys Asp Asn Val
Cys Asp Arg Gly
Cys Asp Val Asn
Cys Glu Ala Gln
Cys Glu Gln Ala
Cys Gly Asp Arg
Cys Gly Arg Asp
Cys Lys Cys Pro
Cys Lys Pro Cys
Cys Asn Asp Val
Cys Asn Val Asp
Cys Pro Cys Lys
Cys Pro Cys Gln
Cys Pro Lys Cys
Cys Pro Gln Cys
Cys Gln Ala Glu
Cys Gln Cys Pro
Cys Gln Glu Ala
Cys Gln Pro Cys
Cys Arg Asp Gly
Cys Arg Gly Asp
Cys Val Asp Asn
Cys Val Asn Asp
Cys Trp Ala Ala
Asp Ala Met Asn
Asp Ala Asn Met
Asp Cys Gly Arg
Asp Cys Asn Val
Asp Cys Arg Gly
Asp Cys Val Asn
Asp Asp Asn Ser
Asp Asp Ser Asn
Asp Gly Cys Arg
Asp Gly Met Gln
Asp Gly Gln Met
Asp Gly Arg Cys
Asp Met Ala Asn
Asp Met Gly Gln
Asp Met Asn Ala
Asp Met Gln Gly
Asp Asn Ala Met
Asp Asn Cys Val
Asp Asn Asp Ser
Asp Asn Met Ala
Asp Asn Ser Asp
Asp Asn Thr Thr
Asp Asn Val Cys
Asp Gln Gly Met
Asp Gln Met Gly
Asp Gln Ser Thr
Asp Gln Thr Ser
Asp Arg Cys Gly
Asp Arg Gly Cys
Asp Ser Asp Asn
Asp Ser Asn Asp
Asp Ser Gln Thr
Asp Ser Thr Gln
Asp Thr Asn Thr
Asp Thr Gln Ser
Asp Thr Ser Gln
Asp Thr Thr Asn
Asp Val Cys Asn
Asp Val Asn Cys
Glu Ala Cys Gln
Glu Ala Gln Cys
Glu Cys Ala Gln
Glu Cys Gln Ala
Glu Gly Met Asn
Glu Gly Asn Met
Glu Met Gly Asn
Glu Met Asn Gly
Glu Asn Gly Met
Glu Asn Met Gly
Glu Asn Ser Thr
Glu Asn Thr Ser
Glu Gln Ala Cys
Glu Gln Cys Ala
Glu Gln Ser Ser
Glu Ser Asn Thr
Glu Ser Gln Ser
Glu Ser Ser Gln
Glu Ser Thr Asn
Glu Thr Asn Ser
Glu Thr Ser Asn
Gly Cys Asp Arg
Gly Cys Arg Asp
Gly Asp Cys Arg
Gly Asp Met Gln
Gly Asp Gln Met
Gly Asp Arg Cys
Gly Glu Met Asn
Gly Glu Asn Met
Gly Gly Met Trp
Gly Gly Trp Met
Gly Met Asp Gln
Gly Met Glu Asn
Gly Met Gly Trp
Gly Met Asn Glu
Gly Met Gln Asp
Gly Met Trp Gly
Gly Asn Glu Met
Gly Asn Met Glu
Gly Asn Pro Tyr
Gly Asn Tyr Pro
Gly Pro Asn Tyr
Gly Pro Tyr Asn
Gly Gln Asp Met
Gly Gln Met Asp
Gly Arg Cys Asp
Gly Arg Asp Cys
Gly Ser Thr Trp
Gly Ser Trp Thr
Gly Thr Ser Trp
Gly Thr Trp Ser
Gly Trp Gly Met
Gly Trp Met Gly
Gly Trp Ser Thr
Gly Trp Thr Ser
Gly Tyr Asn Pro
Gly Tyr Pro Asn
Lys Cys Cys Pro
Lys Cys Pro Cys
Lys Pro Cys Cys
Met Ala Asp Asn
Met Ala Asn Asp
Met Asp Ala Asn
Met Asp Gly Gln
Met Asp Asn Ala
Met Asp Gln Gly
Met Glu Gly Asn
Met Glu Asn Gly
Met Gly Asp Gln
Met Gly Glu Asn
Met Gly Gly Trp
Met Gly Asn Glu
Met Gly Gln Asp
Met Gly Trp Gly
Met Asn Ala Asp
Met Asn Asp Ala
Met Asn Glu Gly
Met Asn Gly Glu
Met Gln Asp Gly
Met Gln Gly Asp
Met Trp Gly Gly
Asn Ala Asp Met
Asn Ala Met Asp
Asn Cys Asp Val
Asn Cys Val Asp
Asn Asp Ala Met
Asn Asp Cys Val
Asn Asp Asp Ser
Asn Asp Met Ala
Asn Asp Ser Asp
Asn Asp Thr Thr
Asn Asp Val Cys
Asn Glu Gly Met
Asn Glu Met Gly
Asn Glu Ser Thr
Asn Glu Thr Ser
Asn Gly Glu Met
Asn Gly Met Glu
Asn Gly Pro Tyr
Asn Gly Tyr Pro
Asn Met Ala Asp
Asn Met Asp Ala
Asn Met Glu Gly
Asn Met Gly Glu
Asn Pro Gly Tyr
Asn Pro Tyr Gly
Asn Ser Asp Asp
Asn Ser Glu Thr
Asn Ser Thr Glu
Asn Thr Asp Thr
Asn Thr Glu Ser
Asn Thr Ser Glu
Asn Thr Thr Asp
Asn Val Cys Asp
Asn Val Asp Cys
Asn Tyr Gly Pro
Asn Tyr Pro Gly
Pro Cys Cys Lys
Pro Cys Cys Gln
Pro Cys Lys Cys
Pro Cys Gln Cys
Pro Gly Asn Tyr
Pro Gly Tyr Asn
Pro Lys Cys Cys
Pro Asn Gly Tyr
Pro Asn Tyr Gly
Pro Gln Cys Cys
Pro Tyr Gly Asn
Pro Tyr Asn Gly
Gln Ala Cys Glu
Gln Ala Glu Cys
Gln Cys Ala Glu
Gln Cys Cys Pro
Gln Cys Glu Ala
Gln Cys Pro Cys
Gln Asp Gly Met
Gln Asp Met Gly
Gln Asp Ser Thr
Gln Asp Thr Ser
Gln Glu Ala Cys
Gln Glu Cys Ala
Gln Glu Ser Ser
Gln Gly Asp Met
Gln Gly Met Asp
Gln Met Asp Gly
Gln Met Gly Asp
Gln Pro Cys Cys
Gln Ser Asp Thr
Gln Ser Glu Ser
Gln Ser Ser Glu
Gln Ser Thr Asp
Gln Thr Asp Ser
Gln Thr Ser Asp
Arg Cys Asp Gly
Arg Cys Gly Asp
Arg Asp Cys Gly
Arg Asp Gly Cys
Arg Gly Cys Asp
Arg Gly Asp Cys
Ser Ala Ser Trp
Ser Ala Trp Ser
Ser Asp Asp Asn
Ser Asp Asn Asp
Ser Asp Gln Thr
Ser Asp Thr Gln
Ser Glu Asn Thr
Ser Glu Gln Ser
Ser Glu Ser Gln
Ser Glu Thr Asn
Ser Gly Thr Trp
Ser Gly Trp Thr
Ser Asn Asp Asp
Ser Asn Glu Thr
Ser Asn Thr Glu
Ser Gln Asp Thr
Ser Gln Glu Ser
Ser Gln Ser Glu
Ser Gln Thr Asp
Ser Ser Ala Trp
Ser Ser Glu Gln
Ser Ser Gln Glu
Ser Ser Trp Ala
Ser Thr Asp Gln
Ser Thr Glu Asn
Ser Thr Gly Trp
Ser Thr Gln Asp
Ser Thr Trp Gly
Ser Trp Ala Ser
Ser Trp Gly Thr
Ser Trp Ser Ala
Ser Trp Thr Gly
Thr Asp Asn Thr
Thr Asp Gln Ser
Thr Asp Ser Gln
Thr Asp Thr Asn
Thr Glu Asn Ser
Thr Glu Ser Asn
Thr Gly Ser Trp
Thr Gly Trp Ser
Thr Asn Asp Thr
Thr Asn Glu Ser
Thr Asn Ser Glu
Thr Asn Thr Asp
Thr Gln Asp Ser
Thr Gln Ser Asp
Thr Ser Asp Gln
Thr Ser Glu Asn
Thr Ser Gly Trp
Thr Ser Asn Glu
Thr Ser Gln Asp
Thr Ser Trp Gly
Thr Thr Asp Asn
Thr Thr Asn Asp
Thr Trp Gly Ser
Thr Trp Ser Gly
Val Cys Asp Asn
Val Cys Asn Asp
Val Asp Cys Asn
Val Asp Asn Cys
Val Asn Cys Asp
Val Asn Asp Cys
Trp Ala Ala Cys
Trp Ala Cys Ala
Trp Ala Ser Ser
Trp Cys Ala Ala
Trp Gly Gly Met
Trp Gly Met Gly
Trp Gly Ser Thr
Trp Gly Thr Ser
Trp Met Gly Gly
Trp Ser Ala Ser
Trp Ser Gly Thr
Trp Ser Ser Ala
Trp Ser Thr Gly
Trp Thr Gly Ser
Trp Thr Ser Gly
Tyr Gly Asn Pro
Tyr Gly Pro Asn
Tyr Asn Gly Pro
Tyr Asn Pro Gly
Tyr Pro Gly Asn
Tyr Pro Asn Gly
Crizotinib
L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents > L01E - Protein kinase inhibitors > L01ED - Anaplastic lymphoma kinase (alk) inhibitors C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C164000 - c-Met-targeting Agent C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C1967 - Tyrosine Kinase Inhibitor C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C141136 - ALK Inhibitor C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor D004791 - Enzyme Inhibitors > D047428 - Protein Kinase Inhibitors D000970 - Antineoplastic Agents Crizotinib (PF-02341066) is an orally bioavailable, ATP-competitive ALK and c-Met inhibitor with IC50s of 20 and 8 nM, respectively. Crizotinib inhibits tyrosine phosphorylation of NPM-ALK and tyrosine phosphorylation of c-Met with IC50s of 24 and 11 nM in cell-based assays, respectively. Crizotinib is also a ROS1 inhibitor. Crizotinib has effective tumor growth inhibition[1][2][3].
Glisoxepid
A - Alimentary tract and metabolism > A10 - Drugs used in diabetes > A10B - Blood glucose lowering drugs, excl. insulins > A10BB - Sulfonylureas C78276 - Agent Affecting Digestive System or Metabolism > C29711 - Anti-diabetic Agent > C97936 - Sulfonylurea Antidiabetic Agent
(5R-cis)-Toluene-4-sulfonic acid 5-(2,4-difluorophenyl)-5-(1H-1,2,4-triazol-1-yl)methyltetrahydrofuran-3-ylmethyl ester
Sarmoxicillin
D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D047090 - beta-Lactams D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D010406 - Penicillins D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D007769 - Lactams
Methyl3,4,6-tri-O-acetyl-2-deoxy-2-phthalimido-b-D-glucopyranoside
benzyl (2R)-3-(4-methylphenyl)sulfonyloxy-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoate
Pyrrolo[1,2-a]pyrazine-3-acetic acid, 7-[[(9H-fluoren-9-ylmethoxy)carbonyl]amino]octahydro-1,4-dioxo-, (3S,7S,8aS)- (9CI)
4-[4-(4-Chlorophenyl)-4-hydroxypiperidin-1-yl]-2,2-diphenyl-butyric acid
2,5-Anhydro-1,3,4-trideoxy-2-C-(2,4-difluorophenyl)-4-[[[(4-methylphenyl)sulfonyl]oxy]methyl]-1-(1H-1,2,4-triazol-1-yl)-D-erythro-pentitol
Bictegravir
C254 - Anti-Infective Agent > C281 - Antiviral Agent > C1660 - Anti-HIV Agent
B-spiro[9H-fluorene-9,8-indolo[3,2,1-de]acridin]-2-yl-Boronic acid
B-spiro[9H-Fluorene-9,8-indolo[3,2,1-de]acridin]-3-ylboronic acid
B-spiro[9H-Fluorene-9,8-indolo[3,2,1-de]acridin]-4-ylboronic acid
M2698 free base
C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C61074 - Serine/Threonine Kinase Inhibitor C274 - Antineoplastic Agent > C1742 - Angiogenesis Inhibitor > C155764 - AKT Inhibitor C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor M2698 (MSC2363318A) is an orally active, ATP competitive, selective p70S6K and Akt dual-inhibitor with IC50s of 1 nM for p70S6K, Akt1 and Akt3. M2698 can cross the blood-brain barrier and has anti-cancer activity[1].
Brilaroxazine
C78272 - Agent Affecting Nervous System > C29710 - Antipsychotic Agent Brilaroxazine (RP5603) is a potent and orally active multimodal dopamine (DA)/serotonin (5-HT) modulator. Brilaroxazine is a partial agonist of dopamine (DA) D2, D3, and D4?receptors, 5-HT1A (Ki=1.5 nM)?and 5-HT2A (Ki=2.5 nM), and has antagonist activity at 5-HT2B (Ki=0.19 nM), and 5-HT7 (Ki=2.7 nM) receptors[1]. Brilaroxazine is an atypical antipsychotic agent, and has the potential to improve cognitive impairments in neuropsychiatric and neurological diseases in vivo[2].
N-{4-Methyl-3-[(3-Pyrimidin-4-Ylpyridin-2-Yl)amino]phenyl}-3-(Trifluoromethyl)benzamide
Mevidalen
C26170 - Protective Agent > C1509 - Neuroprotective Agent LY3154207 is a potent, subtype selective, and orally available human dopamine D1 receptor positive allosteric modulator (PAM) with minimal allosteric agonist activity (EC50=3 nM)[1].
(E)-N-ethyl-6,6-dimethyl-N-[[3-[(4-thiophen-3-ylthiophen-2-yl)methoxy]phenyl]methyl]hept-2-en-4-yn-1-amine
NB-598 is a potent and competitive inhibitor of squalene epoxidase (SE), and suppresses triglyceride biosynthesis through the farnesol pathway. NB-598 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
N-[2,6-Bis(1-methylethyl)phenyl]-N-[4-[(4-nitrophenyl)thio]phenyl]urea
VULM 1457 is a potent inhibitor of cholesterol acyltransferase (acyl-CoA). VULM1457 significantly reduces production and secretion of adrenomedullin (AM) and down-regulates AM receptors on human hepatoblastic cells. VULM 1457 has remarkable hypolipidaemic activity and improves the overall myocardial ischaemia-reperfusion injury outcomes. VULM 1457 has the potential for the research of diabetes mellitus and hypercholesterolaemia[1][2].
N-(3,5-dimethylphenyl)-2-[[4-(4-fluorophenyl)-5-[(1-methyl-2-pyrrolyl)methyl]-1,2,4-triazol-3-yl]thio]acetamide
N-(9,9-dimethyl-7-oxo-8,10-dihydronaphtho[1,2-b]benzofuran-5-yl)-4-methoxybenzenesulfonamide
1-{[(3R)-3-methyl-4-({4-[(1S)-2,2,2-trifluoro-1-hydroxy-1-methylethyl]phenyl}sulfonyl)piperazin-1-yl]methyl}cyclopropanecarboxamide
N-cyclopropyl-3-{[1-(2,4-difluorophenyl)-7-methyl-6-oxo-6,7-dihydro-1H-pyrazolo[3,4-b]pyridin-4-yl]amino}-4-methylbenzamide
N-Hydroxy-1-(4-methoxyphenyl)sulfonyl-4-benzyloxycarbonyl-piperazine-2-carboxamide
2-[[5-[2-(2-amino-4-oxo-5,6,7,8-tetrahydro-3H-pyrido[2,3-d]pyrimidin-6-yl)ethyl]thiophene-2-carbonyl]amino]pentanedioic acid
N-[5-(4-chlorophenyl)-7-(4-methoxyphenyl)-1,5,6,7-tetrahydro-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl]-2-furancarboxamide
(2S)-3-methyl-2-[[(3-methylphenyl)-oxomethyl]amino]butanoic acid (4-oxo-2-pyrimido[2,1-b][1,3]benzothiazolyl)methyl ester
N-[[4-[oxo-[4-(phenylmethyl)-1-piperazinyl]methyl]phenyl]methyl]benzenesulfonamide
[4-(2,5-Diphenyl-7-pyrazolo[1,5-a]pyrimidinyl)-1-piperazinyl]-(3-furanyl)methanone
2-[[[3-Methyl-4-[[2-(3-nitrophenoxy)-1-oxoethyl]amino]phenyl]-oxomethyl]amino]benzoic acid
trans-4-[({2-[(2-oxo-3-phenyl-2H-chromen-7-yl)oxy]propanoyl}amino)methyl]cyclohexanecarboxylic acid
ethyl 5-bromo-3-[3-(3,3-dimethylpiperidin-1-yl)propanoylamino]-1H-indole-2-carboxylate
N-[3-(3,5-dimethyl-1-pyrazolyl)-2-hydroxypropyl]-N-(4-methylphenyl)-2-naphthalenesulfonamide
(E)-2-Cyano-3-(2-dibenzylamino-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl)-N-methyl-acrylamide
(E)-2-(benzenesulfonyl)-3-[9-methyl-2-(4-methylpiperazin-1-yl)-4-oxopyrido[1,2-a]pyrimidin-3-yl]prop-2-enenitrile
N-[2-(2,5-dimethoxyphenyl)-1-({2-[(5-methyl-2-thienyl)methylene]hydrazino}carbonyl)vinyl]benzamide
2-(2-Furanylmethylamino)benzoic acid [2-[(3-cyano-6-methyl-4,5,6,7-tetrahydro-1-benzothiophen-2-yl)amino]-2-oxoethyl] ester
2-(2-Methoxyanilino)-8-[(3-methyl-1-piperidinyl)-oxomethyl]-[1,3,4]thiadiazolo[2,3-b]quinazolin-5-one
4-[4-(4-Methylphenyl)sulfonyl-1-piperidinyl]-2-thiophen-2-ylquinazoline
7-methoxycrinamabine Trifluoroacetic acid
A natural product found in Crinum asiaticum var. sinicum.
3-[4-[(E,3E)-3-(1,3,3-trimethylindol-2-ylidene)prop-1-enyl]quinolin-1-ium-1-yl]propane-1-sulfonic acid
(1S,9R,10R,11R)-10-(hydroxymethyl)-6-oxo-N-[(1R)-1-phenylethyl]-12-(3,3,3-trifluoropropyl)-7,12-diazatricyclo[7.2.1.02,7]dodeca-2,4-diene-11-carboxamide
(2S,3S,3aR,9bR)-7-(2-fluorophenyl)-3-(hydroxymethyl)-6-oxo-1-(pyridin-4-ylmethyl)-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxylic acid methyl ester
methyl (2S,3S,3aR,9bR)-1-[(3-fluorophenyl)methyl]-3-(hydroxymethyl)-6-oxo-7-pyridin-3-yl-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxylate
(1R,9S,10S,11S)-5-(2-fluorophenyl)-10-(hydroxymethyl)-6-oxo-12-(pyridine-3-carbonyl)-7,12-diazatricyclo[7.2.1.02,7]dodeca-2,4-diene-11-carboxylic acid
(1R,9S,10S,11S)-10-(hydroxymethyl)-6-oxo-N-[(1R)-1-phenylethyl]-12-(3,3,3-trifluoropropyl)-7,12-diazatricyclo[7.2.1.02,7]dodeca-2,4-diene-11-carboxamide
(2S,3S,3aR,9bR)-7-(3-fluorophenyl)-3-(hydroxymethyl)-6-oxo-1-(pyridine-2-carbonyl)-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxylic acid
(1S,9R,10R,11R)-N-ethyl-10-(hydroxymethyl)-6-oxo-5-phenyl-12-(3,3,3-trifluoropropyl)-7,12-diazatricyclo[7.2.1.02,7]dodeca-2,4-diene-11-carboxamide
methyl (1R,9S,10S,11S)-5-(4-fluorophenyl)-10-(hydroxymethyl)-6-oxo-12-(pyridin-3-ylmethyl)-7,12-diazatricyclo[7.2.1.02,7]dodeca-2,4-diene-11-carboxylate
2-[(2R,5S,6R)-6-(hydroxymethyl)-5-[(3-methoxyphenyl)sulfonylamino]-2-oxanyl]-N-(pyridin-4-ylmethyl)acetamide
2-[(2S,5S,6R)-6-(hydroxymethyl)-5-[(3-methoxyphenyl)sulfonylamino]-2-oxanyl]-N-(pyridin-4-ylmethyl)acetamide
2-[(2S,5R,6R)-6-(hydroxymethyl)-5-[(3-methoxyphenyl)sulfonylamino]-2-oxanyl]-N-(pyridin-4-ylmethyl)acetamide
(1S,9R,10R,11R)-10-(hydroxymethyl)-6-oxo-N-[(1S)-1-phenylethyl]-12-(3,3,3-trifluoropropyl)-7,12-diazatricyclo[7.2.1.02,7]dodeca-2,4-diene-11-carboxamide
(2R,3R,3aS,9bS)-7-(3-fluorophenyl)-3-(hydroxymethyl)-6-oxo-1-[oxo(2-pyridinyl)methyl]-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxylic acid
(1R,9S,10S,11S)-N-ethyl-10-(hydroxymethyl)-6-oxo-5-phenyl-12-(3,3,3-trifluoropropyl)-7,12-diazatricyclo[7.2.1.02,7]dodeca-2,4-diene-11-carboxamide
methyl (1S,9R,10R,11R)-5-(4-fluorophenyl)-10-(hydroxymethyl)-6-oxo-12-(pyridin-3-ylmethyl)-7,12-diazatricyclo[7.2.1.02,7]dodeca-2,4-diene-11-carboxylate
(2S,3S,3aR,9bR)-3-(hydroxymethyl)-N,N-dimethyl-6-oxo-7-phenyl-1-(3,3,3-trifluoropropyl)-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide
2-[(2S,5R,6S)-6-(hydroxymethyl)-5-[(3-methoxyphenyl)sulfonylamino]-2-oxanyl]-N-(pyridin-4-ylmethyl)acetamide
2-[(2R,5R,6S)-6-(hydroxymethyl)-5-[(3-methoxyphenyl)sulfonylamino]-2-oxanyl]-N-(pyridin-4-ylmethyl)acetamide
2-[(2S,5S,6S)-6-(hydroxymethyl)-5-[(3-methoxyphenyl)sulfonylamino]-2-oxanyl]-N-(pyridin-4-ylmethyl)acetamide
2-[(2R,5R,6R)-6-(hydroxymethyl)-5-[(3-methoxyphenyl)sulfonylamino]-2-oxanyl]-N-(pyridin-4-ylmethyl)acetamide
2-[(2R,5S,6S)-6-(hydroxymethyl)-5-[(3-methoxyphenyl)sulfonylamino]-2-oxanyl]-N-(pyridin-4-ylmethyl)acetamide
(1S,9R,10R,11R)-5-(2-fluorophenyl)-10-(hydroxymethyl)-6-oxo-12-(pyridine-3-carbonyl)-7,12-diazatricyclo[7.2.1.02,7]dodeca-2,4-diene-11-carboxylic acid
(1R,9S,10S,11S)-10-(hydroxymethyl)-6-oxo-N-[(1S)-1-phenylethyl]-12-(3,3,3-trifluoropropyl)-7,12-diazatricyclo[7.2.1.02,7]dodeca-2,4-diene-11-carboxamide
(2R,3R,3aS,9bS)-7-(2-fluorophenyl)-3-(hydroxymethyl)-6-oxo-1-(pyridin-4-ylmethyl)-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxylic acid methyl ester
(2R,3R,3aS,9bS)-1-[(3-fluorophenyl)methyl]-3-(hydroxymethyl)-6-oxo-7-(3-pyridinyl)-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxylic acid methyl ester
(2R,3R,3aS,9bS)-3-(hydroxymethyl)-N,N-dimethyl-6-oxo-7-phenyl-1-(3,3,3-trifluoropropyl)-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide
(2E)-2-[[3-methoxy-4-(3-methylbutoxy)phenyl]methylidene]-6-phenyl-[1,3]thiazolo[3,2-b][1,2,4]triazine-3,7-dione
Ethyl 4,7-DI(para-ethoxyphenyl)-1,2,5-thiadiazolo(3,4-C)pyridine-6-carboxylate
NP10679
NP10679 is a selective, pH dependent GluN2B subunit-specific N-methyl-D-aspartate (NMDA) receptor inhibitor with high oral bioavailability and good brain penetration. NP10679 inhibits GluN2B with IC50s of 23 and 142 nM at pH 6.9 and 7.6, respectively. NP10679 is a histamine H1 antagonist and a hERG channel inhibitor with IC50s of 73 and 620 nM, respectively. NP10679 is a reversible inhibitor of human liver CYP enzymes[1].
OPC-14523 (hydrochloride)
OPC-14523 hydrochloride is an orally active sigma and 5-HT1A receptor agonist, with high affinity for sigma receptors (σ1/2 IC50=47/56 nM), the 5-HT1A receptor (IC50=2.3 nM), and the 5-HT transporter (IC50=80 nM). OPC-14523 hydrochloride shows antidepressant-like activity[1][2].